top of page
AMD101 topical ophthalmic products
Small molecule compound which has been safe in human for more than 30 years
Age-related Macular degeneration (AMD)
Patients with AMD lose vision acuity. More than 3 million patients suffer from AMD.
Inhibition of VEGF and neovascularization
Delivery to the back of the eye
The active ingredient was efficiently and rapidly delivered to the back of the eyes in animal studies.
Lucentis and Eylea each with billions in sales require an injection into the vitreous of the eye because they are protein products. Many patients fear the pain of the repeated intravitreal injections. AMD101 is a topical product that utilizes the same approach as the established drugs, inhibition of VEGF. Home treatment using AMD101 topical ophthalmic products will be available for the disease when the products will be approved for marketing.
A Japan patent of AMD101 topical ophthalmic products has been issued in Apr, 2021. A new PCT patent application for AMD101 topical products has been published in Jun, 2022.
bottom of page